Login to Your Account



Avastin's Breast Cancer Bid Set Back One Year By FDA

By Randall Osborne


Tuesday, September 12, 2006
As Genentech Inc. hinted earlier, marketing clearance of Avastin for breast cancer has been pushed back by the FDA's request for an independent review of patient scans from the pivotal trial, and satisfying the agency could take longer than analysts expected. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription